Your Blood Pressure Target Is Wrong: What SPRINT Changed and Why Most Patients Don't Know
By Akash S. Chauhan | First Principles Healthspan, Issue 04
If your doctor has told you your blood pressure is "fine" at 128/80, there is a reasonable chance they are measuring against a target that a landmark 2015 trial rendered obsolete. The trial was called SPRINT. It was stopped early because the benefits of treating to a lower target were so clear that continuing to randomize people to the higher target was considered unethical. Its results have been incorporated into major guidelines and ignored by the majority of primary care practices in roughly equal measure.
Understanding what SPRINT showed — and what the evidence around blood pressure more broadly says — is one of the highest-leverage pieces of cardiovascular literacy available to someone optimizing for healthspan.
Why this matters
Hypertension is the single most prevalent modifiable cardiovascular risk factor globally and among the top contributors to all-cause mortality. Its relationship with vascular disease is not dichotomous — it is not that you either "have" hypertension or you do not, and the former kills you. It is continuous, log-linear, and starts at blood pressures well below what was historically considered elevated.
Lewington et al. (2002) published a prospective meta-analysis in The Lancet synthesizing data from one million adults across 61 studies and spanning four decades (PMID: 12493255). Their conclusion was unambiguous: the relationship between usual blood pressure and vascular mortality is continuous, graded, and extends throughout the normal range down to at least 115 mmHg systolic and 75 mmHg diastolic. There is no observed threshold below which lower blood pressure stops being protective. Every 20 mmHg increment in systolic BP doubles the risk of stroke death and coronary heart disease death across mid-life.
The question "do I have hypertension?" is the wrong question. The right question is "what is my blood pressure doing to my vascular tree, right now, and what would a lower number do to my 20-year trajectory?"
What SPRINT showed
The SPRINT trial (Systolic Blood Pressure Intervention Trial) was a large, well-designed, multicenter randomized controlled trial published in the New England Journal of Medicine in 2015 (PMID: 26551272). It enrolled 9,361 adults aged 50 or older with elevated cardiovascular risk (but without diabetes) and randomized them to two blood pressure targets: the standard target of systolic <140 mmHg or an intensive target of systolic <120 mmHg.
The trial was stopped early at a median follow-up of 3.26 years. The primary composite outcome — myocardial infarction, acute coronary syndrome, stroke, heart failure, or cardiovascular death — was 25% lower in the intensive treatment group. All-cause mortality was 27% lower. These are not small effects. For context, statins in primary prevention typically reduce major cardiovascular events by 25-35% over 5 years — SPRINT achieved a comparable risk reduction through blood pressure management alone, in a population where many participants were already on statins.
The intensive treatment group required an average of three antihypertensive medications to achieve the target versus two in the standard group. There was a higher rate of some adverse events in the intensive group, notably acute kidney injury (though largely transient) and hypotension. These tradeoffs are real and must be weighed individually with a clinician. But for the overall population studied, the mortality and cardiovascular benefit clearly outweighed the harms.
What SPRINT did not show (and why that matters)
SPRINT excluded people with diabetes, prior stroke, polycystic kidney disease, and several other conditions. The results therefore apply most cleanly to higher-risk, non-diabetic adults. The ACCORD trial, which tested intensive BP control in patients with type 2 diabetes, showed weaker cardiovascular benefit (though stroke reduction was significant). This means the evidence is strongest for the population SPRINT actually studied — which encompasses a very large fraction of middle-aged and older adults with any cardiovascular risk factors.
SPRINT also measured blood pressure using an automated, unattended protocol (AOBP), which tends to read approximately 5-7 mmHg lower than the standard clinical measurement where a clinician is in the room. This means the 120 mmHg target in SPRINT corresponds roughly to 125-127 mmHg by standard office measurement. This distinction is clinically important and frequently misunderstood — the 2017 ACC/AHA guideline redefinition of hypertension as ≥130/80 (discussed below) was influenced partly by this consideration.
How the guidelines changed — and how clinical practice has lagged
The 2017 ACC/AHA hypertension guideline, published in the Journal of the American College of Cardiology by Whelton et al. (PMID: 29133356), incorporated the SPRINT findings and made several consequential changes. Hypertension was redefined from ≥140/90 to ≥130/80. This reclassified roughly 31 million additional Americans as hypertensive. The guideline recommended the <130/80 target for most treated patients, and acknowledged that the <120 systolic target may be appropriate for selected high-risk individuals based on SPRINT.
This was a significant shift. But knowing that the guideline changed and having clinicians actually act on it are different things. A 2019 analysis using NHANES data suggested that awareness, treatment, and control rates for hypertension in the U.S. had actually declined in the years following guideline publication, despite the stronger evidence base. Inertia is a powerful force in medicine. If your doctor last reviewed your blood pressure against the old <140/90 standard, they may not have flagged a reading of 135/82 as requiring action — under the current evidence base, it likely does.
The home measurement gap
One of the most underappreciated issues in blood pressure management is measurement quality. White coat hypertension — where blood pressure is elevated in a clinical setting but normal elsewhere — affects roughly 15-30% of patients. Masked hypertension — where blood pressure is normal in clinic but elevated at home — is if anything more dangerous because it goes undetected. The only way to resolve the ambiguity is with reliable out-of-office measurement.
A validated upper-arm home cuff costs $30-80 and is one of the higher-value diagnostic tools a healthspan-focused person can own. Taking readings in the morning before medications, after 5 minutes of quiet sitting, in duplicate or triplicate, and averaging across a week gives a far more accurate picture than a single office reading. If you want automated tracking and integration with other biomarkers, Function Health (AFFILIATE_LINK_FUNCTIONHEALTH) includes blood pressure trends in their monitoring framework, and SiPhox (AFFILIATE_LINK_SIPHOX) offers at-home blood draw panels that can provide longitudinal cardiovascular biomarker context alongside your BP data.
What this means in practice
If your systolic blood pressure consistently reads above 120-125 mmHg, the evidence base now suggests you are carrying excess cardiovascular risk — not relative to an arbitrary guideline threshold, but relative to what the Lewington et al. meta-analysis and the SPRINT data together tell us about the continuous risk curve.
The targets that matter for a 45-year-old optimizing healthspan through the next three decades are not the same as the targets that matter for asymptomatic disease detection in a 65-year-old with multiple comorbidities. The former requires a longer time horizon and a lower risk tolerance for cumulative vascular burden. The latter is the population most clinical guidelines are calibrated for.
Lifestyle modifications — sodium restriction, aerobic exercise, weight management, limiting alcohol — can reduce systolic BP by 4-10 mmHg each, and their effects are additive. For many people, consistent implementation of two or three of these measures will move a reading from 130-135 into the low 120s without medication. For others, pharmacological treatment is warranted and carries a strong evidence base: ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics all have mortality outcome data. This is a discussion for a clinician, not a newsletter — but knowing the correct target to aim for is a prerequisite to having that conversation productively.
This Week's One Thing to Do
Measure your blood pressure correctly at home, twice. Sit quietly for 5 minutes. Use a validated upper-arm cuff (not a wrist device — they are less accurate). Take two readings, two minutes apart, and record both. Repeat on three separate mornings before coffee or medication. Average the six readings. This is your resting blood pressure. Now compare it to 120 mmHg systolic — not 140, not 130, but 120, the target that a stopped-early RCT found reduces mortality by 27%.
If you do not own a home cuff, order one today. It is the most cost-effective cardiovascular monitoring tool available.
Until next week, Akash S. Chauhan
Education only. Not medical advice. Always consult a licensed clinician for individual decisions.